Axsome Therapeutics (NASDAQ:AXSM) CEO Sells $2,251,712.61 in Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) CEO Herriot Tabuteau sold 19,719 shares of the business’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $114.19, for a total value of $2,251,712.61. Following the completion of the sale, the chief executive officer directly owned 7,229 shares in the company, valued at $825,479.51. This represents a 73.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Herriot Tabuteau also recently made the following trade(s):

• On Friday, September 12th, Herriot Tabuteau sold 27,907 shares of Axsome Therapeutics stock. The stock was sold at an average price of $118.96, for a total value of $3,319,816.72.
• On Monday, September 15th, Herriot Tabuteau sold 15,254 shares of Axsome Therapeutics stock. The stock was sold at an average price of $117.37, for a total value of $1,790,361.98.

Axsome Therapeutics Stock Up 1.7%

AXSM opened at $118.63 on Friday. Axsome Therapeutics, Inc. has a one year low of $75.56 and a one year high of $139.13. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.51 and a current ratio of 1.57. The stock’s fifty day moving average is $112.74 and its 200-day moving average is $110.51. The company has a market capitalization of $5.92 billion, a PE ratio of -23.40 and a beta of 0.54.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Monday, August 4th. The company reported ($0.92) EPS for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.08. Axsome Therapeutics had a negative return on equity of 283.22% and a negative net margin of 49.88%.The company had revenue of $150.04 million for the quarter, compared to the consensus estimate of $140.02 million. On average, equities analysts predict that Axsome Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd purchased a new position in shares of Axsome Therapeutics during the first quarter valued at $25,000. Quantbot Technologies LP purchased a new position in shares of Axsome Therapeutics during the first quarter valued at $31,000. NBC Securities Inc. purchased a new position in shares of Axsome Therapeutics during the first quarter valued at $31,000. AlphaQuest LLC purchased a new position in shares of Axsome Therapeutics during the first quarter valued at $38,000. Finally, Neo Ivy Capital Management purchased a new position in shares of Axsome Therapeutics during the first quarter valued at $41,000. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on AXSM. Bank of America boosted their price objective on Axsome Therapeutics from $173.00 to $176.00 and gave the stock a “buy” rating in a research note on Tuesday, August 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $150.00 target price on shares of Axsome Therapeutics in a research report on Monday, August 4th. Morgan Stanley assumed coverage on Axsome Therapeutics in a research report on Thursday, July 3rd. They set an “overweight” rating and a $190.00 target price on the stock. Oppenheimer assumed coverage on Axsome Therapeutics in a research report on Tuesday, June 3rd. They set an “outperform” rating and a $185.00 target price on the stock. Finally, Wells Fargo & Company raised Axsome Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 3rd. Two equities research analysts have rated the stock with a Strong Buy rating and thirteen have given a Buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $177.86.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.